

ATTORNEYS AT LAW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michaele A. Cimbala Michaele A. Embala Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey*
Heidi L. Kraus
Edward W. Yee
Albert L. Fero*
Donald R. Banowit
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II*
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono

March 19, 2003

Virgil Lee Beaston'
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
'rank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich'
Lawrence J. Carroli'
George S. Bardmesser
Daniel A. Klein'
Rodney G. Maze
Jason D. Eisenberg
Michael A. Specht
Andrea J. Kamage
Tracy L. Muller'

Jon E. Wright* LuAnne M. Yuricek*

Registered Patent Agents -Karen R. Markowicz Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Angelique G. Uy Boris A. Matvenko Mary B. Iung Katrina Y. Per Bryan L. Skelton Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford W. Brian Edge

Senior Counsel Samuel L. Fox Kenneth C. Bass III Lisa A. Dunner

*Admitted only in Maryland

*Admitted only in Virginia

*Admitted only in Texas

*Practice Limited to
Federal Agencies

P#54

WRITER'S DIRECT NUMBER: (202) 772-8641

INTERNET ADDRESS: hcarlson@skgf.com

Commissioner for Patents Washington, D.C. 20231

Art Unit 1644

Re:

U.S. Utility Patent Application

Appl. No. 08/452,843; Filed: May 30, 1995 For: **HLA Binding Peptides and Their Uses**

Inventors:

SETTE et al.

Our Ref:

2060.0010002/EKS/HCC/M-M

RECEIVED

MAR 2 1 2003

TECH CENTER 1000, 2000

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement;
- 2. Form PTO-1449 one (1) page, citing one (1) document;
- 3. Copy of cited document AS27; and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents March 19, 2003 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Ublemelaren

Helene C. Carlson

Agent for Applicants

Registration No. 47,473

Enclosures

::ODMA\MHODMA\SKGF_DC1;113538;1 SKGF Rev. 2/15/02 dcw RECEIVED MAR 2 1 2003

TECH CENTER 1600/2900

MAR 2 1 2003

THE UNITED STATES PATENT AND TRADEMARK OFF TEGH CENTER 1600/29

In re application of:

SETTE et al.

Appl. No. 08/452,843

Filed: May 30, 1995

For: HLA Binding Peptides and Their

Uses

Confirmation No. 5698

Art Unit: 1644

Examiner: DiBrino, M.

Atty. Docket:

2060.0010002/EKS/HCC/M-M

Second Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Supplemental Information Disclosure Statement filed on October 2, 2002, in connection with the above-captioned application. A copy of the document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d). No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the document has been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Yblendladm

Helene C. Carlson

Agent for Applicants

Registration No. 47,473

Date: 3/19/03

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

::ODMA\MHODMA\SKGF_DC1;113402;1 SKGF Rev. 12/1802 mac; Rev. 03/14/03 svb



SECOND SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 2060.0010002/EKS/HCC/M-M APPLICATION NO. 08/452,843

APPLICANT

Sette et al.
FILING DATE

GROUP 1644

| | | | | | May 30, 1995 | 1 | 644 | |
|--|----------|--|--|----------|---------------|----------|------------|-------------|
| | | | | U.S. PAT | ENT DOCUMENTS | | | |
| EXAMINER INITIAL | | DOCUI | MENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | | |
| | AB | | | | | | | |
| | AC | | | | | ļ | | |
| | AD | | | | | | | |
| | AE | | | | | | REC | EIVED |
| | AF | | | | | | | |
| | AG AH | | | | | <u> </u> | MAR | 2 1 2003 |
| | AI | | | | | | | 1000 |
| | АJ | <u> </u> | | | | | TECH CEN | ER 1600/290 |
| | AK | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | 7.7 | | | | | | | Yes No |
| | AL | | | | | - | | Yes |
| | AM | | | | | | | No |
| | AN | | | | | | | Yes No |
| | | | | | | | | Yes No |
| | AO | | | | | | | Yes |
| | AP | | | | | <u> </u> | | No |
| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | | |
| | AR | | | | | | | |
| | AS | <u>27</u> | Gnjatic, S., et al., "Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules," Eur. J. Immunol. 25:1638-1642, VCH Verlagsgesellschaft mbH (June 1995). | | | | | |
| | AT | | | | | | | |
| EXAMINER | | | | | | DATE | CONSIDERED | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.